english.prescrire.org > Spotlight > 100 most recent > Pembrolizumab (Keytruda°) in urothelial carcinoma


Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the January issue of Prescrire International: Pembrolizumab (Keytruda°) in urothelial carcinoma

FREE DOWNLOAD In this month's sample review: Prescrire's editors rate pembrolizumab (Keytruda°) "Possibly helpful" in certain patients with locally advanced or metastatic urothelial carcinoma.
Full text available for free download.


  • Pembrolizumab (Keytruda°) has been authorised in the EU for use in patients with locally advanced or metastatic urothelial carcinoma, after failure of platinum-based chemotherapy or when cisplatin-containing chemotherapy cannot be used.
  •  POSSIBLY HELPFUL  In a non-blinded comparative randomised trial after failure of platinum-containing chemotherapy, pembrolizumab prolonged survival by about 3 months compared with taxane- or vinflunine-containing chemotherapy. Its adverse effects were different and less frequent.

Full text available for free download.

 ©Prescrire 1 January 2019

"Pembrolizumab (Keytruda°) in urothelial carcinoma" Prescrire Int 2019; 28 (200): 9. (Pdf, free).

Share Share on Facebook Share on Twitter


Partager sur Facebook Partager sur Twitter

Download the full review
Pdf, free
Prescrire's rating:
Prescrire's rating